A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

M Oza, Amit; A Matulonis, Ursula; Alvarez Secord, Angeles; Nemunaitis, John; D Roman, Lynda; P Blagden, Sarah; Banerjee, Susana; P McGuire, William; Ghamande, Sharad; J Birrer, Michael; F Fleming, Gini; Jennifer Markham, Merry; W Hirte, Hal; M Provencher, Diane; Basu, Bristi; Kristeleit, Rebecca; K Armstrong, Deborah; Schwartz, Benjamin; Braly, Patricia; D Hall, Geoff; P Nephew, Kenneth; Jueliger, Simone; Oganesian, Aram; Naim, Sue; Hao, Yong; Keer, Harold; Azab, Mohammad; Matei, Daniela

doi:10.1158/1078-0432.ccr-19-1638

Public

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Shared by NobleBlocks on Mar 1, 2020 • 12:00 AM UTC

Authors:

Amit M Oza

Ursula A Matulonis

Angeles Alvarez Secord

Abstract

PURPOSE: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a second-generation HMA, and carboplatin (G+C) agai...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!